Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
28 hedge funds and large institutions have $56.7M invested in Cymabay Therapeutics in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
8% more funds holding
Funds holding: 26 → 28 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $74.3M → $56.7M (-$17.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.17M |
| 2 |
VAM
Visium Asset Management
New York
|
+$3.98M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
+$3.6M |
| 4 |
Morgan Stanley
New York
|
+$662K |
| 5 |
SIM
Spark Investment Management
New York
|
+$579K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.96M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.24M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.2M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$983K |
| 5 |
Jennison Associates
New York
|
-$695K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
26
A.R.T. Advisors
New York
| $104K | +$145K | +15,129 | New |
|
|
PP
27
PDT Partners
New York
| $87K | +$120K | +12,500 | New |
|
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | – | – | – |
|
|
SAM
29
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$6.96M | -708,585 | Closed |
|
|
SCM
30
Sio Capital Management
New York
| – | -$1.2M | -121,900 | Closed |
|
|
RSCM
31
Rock Springs Capital Management
Baltimore,
Maryland
| – | -$983K | -100,000 | Closed |
|
32
Goldman Sachs
New York
| – | -$418K | -42,563 | Closed |
|
33
ClearBridge Investments
New York
| – | -$17K | -1,760 | Closed |
|
34
Citigroup
New York
| – | -$5K | -482 | Closed |
|
35
UBS Group
Zurich,
Switzerland
| – | -$3K | -329 | Closed |
|
36
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -300 | Closed |
|
CBAY Hedge Fund Activity: Q1 2015 in Review
28 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2015, worth a combined $56.7M — down 24% from $74.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CBAY positions and 8 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6.17M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $6.96M sold.
- 28 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2015, up from 26 in Q4 2014.
- Funds reported $56.7M of Cymabay Therapeutics stock for Q1 2015, down 24% quarter-over-quarter.
- 10 funds opened new Cymabay Therapeutics positions in Q1 2015 and 8 closed out, a net change of +2 holders.
- The largest Cymabay Therapeutics buyer in Q1 2015 was Adage Capital Partners, an estimated $6.17M added.
- The largest Cymabay Therapeutics seller in Q1 2015 was Sectoral Asset Management, an estimated $6.96M sold.
Based on aggregated 13F filings for Q1 2015.